Advertisement
United States  

“News neutrality by unbiased coverage”
One News Page
> >

Immune therapy doubles lung cancer survival rate

bizjournals Tuesday, 17 April 2018
New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found that patients treated with the checkpoint inhibitor pembrolizumab, or Keytruda, made by Merck, along with chemotherapy  were 51 percent less likely to die compared with patients that only received chemotherapy, The Washington Post reports. The study…
0
shares
ShareTweetSavePostSend
 
Source: Wochit News - < > Embed
News video: Lung Cancer Patients Fair Better with Immune Therapy

▶ Lung Cancer Patients Fair Better with Immune Therapy 00:45

According to a new report, lung cancer patients live longer while on immune therapy. Using a combination of immunotherapy drugs, doctors found that pre-treating lung cancer patients before surgery can help eat away at tumors, while helping patients recover from the affects of chemotherapy. A lung...

You Might Like


Tweets about this


Other recent news in Business

Jack Ma said Trump's trade war with China will wreck ALIBABA's plans to help create 1 million US jobs (BABA)Lawmaker: US SENATE, staff targeted by state-backed hackers
NEW YORK REVIEW OF BOOKS editor out week after publishing widely criticized #MeToo essayFLORENCE Flooding Hits North Carolina Hog Farms Hard

Recent related videos

Lung cancer mortality rate among women may spike by 40% by 2030 [Video]Lung cancer mortality rate among women may spike by 40% by 2030

New Delhi, Aug 02 (ANI): According to a new research study, lung cancer mortality rates among women could increase by 43 per cent by 2030. These findings have been analysed from the data from 52..

Health Tips -   01:10

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2018 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+  •  FOLLOW us on Pinterest